Melbourne, Nov 18, 2009 (ABN Newswire) - Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced today that the first group of patients who received the lowest dose of Revascor(TM), the proprietary “off-the-shelf” adult stem cell product for heart failure, continued to show sustained improvement in heart muscle function at six months.
